Cargando…

Long-term outcomes and risk factors of thyroid dysfunction during pegylated interferon and ribavirin treatment in patients with chronic hepatitis C infection in Taiwan

BACKGROUND: This study aimed to investigate the occurrence and risk factors of thyroid dysfunction (TD) in patients with chronic hepatitis C (CHC) infection in Taiwan. METHODS: The data in this study were obtained from the Taiwan National Health Insurance Research (Taiwan NHIR) database between 2001...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Yu-Kang, Tseng, Yuan-Tsung, Chen, Kou-Huang, Chen, Kow-Tong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6451221/ https://www.ncbi.nlm.nih.gov/pubmed/30953492 http://dx.doi.org/10.1186/s12902-019-0362-7

Ejemplares similares

Pegylated Interferon and Ribavirin Treatment for Hepatitis C Virus Infection
por: Kagawa, Tatehiro, et al.
Publicado: (2010)

Pegylated Interferon and Ribavirin in the Retreatment of Chronic Hepatitis C in Korea
por: Cho, Hyun Chin, et al.
Publicado: (2013)

Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin
por: Carvalho-Filho, Roberto J, et al.
Publicado: (2010)

Thyroid disturbances in children treated with combined pegylated interferon-alpha and ribavirin for chronic hepatitis C
por: Rashed, Yasser K., et al.
Publicado: (2020)

Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin
por: Abbas, Zaigham, et al.
Publicado: (2013)

Thrombocytopenia in pegylated interferon and ribavirin combination therapy for chronic hepatitis C
por: Aizawa, Nobuhiro, et al.
Publicado: (2013)

Retreatment of hepatitis C patients with pegylated interferon combined with ribavirin in non-responders to interferon plus ribavirin. Is it different in real life?
por: Gonçales, Fernando L, et al.
Publicado: (2010)

Cryptococcal meningitis in a patient with chronic hepatitis C treated with pegylated-interferon and ribavirin
por: Lee, Tae-Hee, et al.
Publicado: (2014)

Effects of Host and virus related factors on Interferon-α+ribavirin and Pegylated-interferon+ribavirin treatment outcomes in Chronic Hepatitis C patients
por: Akram, Madiha, et al.
Publicado: (2011)

Subcutaneous Sarcoidosis during Pegylated Interferon Alfa and Ribavirin Treatment for Chronic Hepatitis C
por: Rodríguez-Lojo, R., et al.
Publicado: (2010)

Organizing Pneumonia Associated with Pegylated Interferon α and Ribavirin Therapy
por: Chopra, Amit, et al.
Publicado: (2015)

Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy
por: Pradat, Pierre, et al.
Publicado: (2015)

Interferon-Alpha Induced and Ribavirin Induced Thyroid Dysfunction in Patients with Chronic Hepatitis C
por: Nadeem, Amina, et al.
Publicado: (2010)

Autoimmune Hepatitis Triggered by Treatment With Pegylated Interferon α-2a and Ribavirin for Chronic Hepatitis C
por: Rathi, Chetan, et al.
Publicado: (2015)

Effects of Pegylated Interferon/Ribavirin on Bone Turnover Markers in HIV/Hepatitis C Virus-Coinfected Patients
por: Bedimo, Roger, et al.
Publicado: (2016)

Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin
por: Asselah, Tarik, et al.
Publicado: (2010)

Cutaneous Sarcoidosis: An Uncommon Side Effect of Pegylated Interferon and Ribavirin Use for Chronic Hepatitis C
por: Martins, Elson Vidal, et al.
Publicado: (2009)

Expectoration of Large Bronchial Casts Secondary to the Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin
por: de Araújo, Evaldo Stanislau Affonso, et al.
Publicado: (2010)

Hepatitis C virus core protein substitutions affect the response to pegylated-interferon and ribavirin therapy
por: Alhamlan, Fatimah S, et al.
Publicado: (2014)

Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C
por: Karino, Y, et al.
Publicado: (2014)

Retreatment of Patients Nonresponsive to Pegylated Interferon and Ribavirin with Daily High-Dose Consensus Interferon
por: Meyer, Douglas F., et al.
Publicado: (2010)

Efficacy of pegylated interferon plus ribavirin in combination with corticosteroid for two cases of combined hepatitis C and autoimmune hepatitis
por: Oeda, Satoshi, et al.
Publicado: (2012)

Pegylated Interferon and Ribavirin Dosing Strategies to Enhance Sustained Virologic Response
por: Chak, Eric, et al.
Publicado: (2010)

Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin
por: Hartl, Janine, et al.
Publicado: (2012)

Predictors of Pegylated Interferon Alpha and Ribavirin Efficacy and Long-Term Assessment of Relapse in Patients With Chronic Hepatitis C: A One-Center Experience From China
por: Wu, Qin, et al.
Publicado: (2015)

Large Intestine Histopathology of Pegylated-Interferon-Alpha Plus Ribavirin Treated Chronic Hepatitis C Patients
por: Pantazis, Konstantinos D., et al.
Publicado: (2008)

Hepatitis C Viral Kinetics as a Determinant of Stopping Pegylated Interferon and Ribavirin in Genotype 1 Infection
por: Kim, Do Young
Publicado: (2014)

Extensive Psoriasis Induced by Pegylated Interferon Alfa-2a and Ribavirin in the Treatment of Chronic Hepatitis C
por: Kim, Gun-Wook, et al.
Publicado: (2013)

Factors influencing therapeutic response to pegylated interferon plus ribavirin in the different genotypes of chronic hepatitis C
por: Heidari, Mehdi, et al.
Publicado: (2014)

Effectiveness of sofosbuvir/pegylated-interferon plus ribavirin in treatment of hepatitis C virus genotype 4 patients
por: Abdel-Moneim, Adel, et al.
Publicado: (2018)

Pegylated interferon may be considered in chronic viral hepatitis E resistant to ribavirin in kidney transplant recipients
por: Ollivier-Hourmand, I., et al.
Publicado: (2020)

Analysis of Different Types of Interferon-Associated Retinopathy in Patients with Chronic Hepatitis C Virus Infection Treated with Pegylated Interferon Plus Ribavirin
por: Wu, Chia-Min, et al.
Publicado: (2021)

The Role of Interleukin-28b Gene Polymorphisms in Chinese Patients With Chronic Hepatitis C Treated With Pegylated Interferon and Ribavirin
por: Mi, Yin, et al.
Publicado: (2014)

Concurrent Autoimmune Hepatitis and Grave's Disease in Hepatitis C during Pegylated Interferon α-2a and Ribavirin Therapy
por: Trikudanathan, Guru V., et al.
Publicado: (2011)

Occult hepatitis B infection in egyptian chronic hepatitis C patients: prevalence, impact on pegylated interferon/ribavirin therapy
por: Emara, Mohamed H, et al.
Publicado: (2010)

Cutaneous side effects of combination therapy of pegylated interferon 2α and ribavirin
por: Raducan, Anca, et al.
Publicado: (2014)

Long-term surveillance of liver histological changes in chronic hepatitis C patients completing pegylated interferon-α plus ribavirin therapy: an observational cohort study
por: Hsieh, Ming-Han, et al.
Publicado: (2022)

Fatal Neutropenic Enterocolitis during Pegylated Interferon and Ribavirin Combination Therapy for Chronic Hepatitis C Virus Infection
por: Kim, Ji Hun, et al.
Publicado: (2009)

Durability of a sustained virological response in chronic hepatitis C patients treated with pegylated interferon alfa and ribavirin
por: Choi, Sang Bun, et al.
Publicado: (2011)

Dysregulation of IFN System Can Lead to Poor Response to Pegylated Interferon and Ribavirin Therapy in Chronic Hepatitis C
por: Onomoto, Koji, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_krodag9aipr3qjjin1oi9ftlsf